Agilent Technologies
Agilent Technologies, Inc. (NYSE: A) provides instruments, software, services and consumables for laboratory workflows in life sciences, diagnostics and applied markets. Its customers include pharmaceutical and biopharmaceutical companies, clinical and research laboratories, academic and government institutions, and… From the company’s description.
In fiscal 2025, Agilent Technologies reported revenue of $6.95B, up 6.7% from fiscal 2024, and net income of $1.30B. Its operating margin was 21.3%, and operations generated $1.56B in cash. Over the twelve months to Jul 31, 2026, revenue was $7.37B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Agilent Technologies does
In the company’s own words
Agilent Technologies, Inc. (NYSE: A) provides instruments, software, services and consumables for laboratory workflows in life sciences, diagnostics and applied markets. Its customers include pharmaceutical and biopharmaceutical companies, clinical and research laboratories, academic and government institutions, and organizations in food, environmental, chemical and advanced-materials markets. The company operates three reportable segments: Life Sciences and Diagnostics Markets, which provides research and diagnostic tools and specialty contract development and manufacturing services; Agilent CrossLab, which offers laboratory services, consumables, software and automation; and Applied Markets, which supplies analytical instruments and software. Its products include chromatography and mass spectrometry systems, pathology and genomics solutions, gas chromatography and spectroscopy instruments, vacuum technologies, and refurbished instruments. CrossLab services include instrument maintenance, repair, training and compliance support, while its OpenLab software supports laboratory data and workflows. As of October 31, 2025, Agilent employed approximately 18,100 people worldwide. Its brands include BIOVECTRA, Dako, Seahorse, xCELLigence, NovoCyte and BioTek.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- SANTA CLARA, CA
- Fiscal year end
- October
- CIK
- 1090872
- SIC
- 3826
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Agilent Technologies — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Agilent Technologies’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Agilent Technologies’s bonds, as funds hold them
Funds report holding 7 issues of Agilent Technologies’s debt, $466.31M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 3.46%, maturing 2026 to 2034.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Agilent Technologies and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Agilent Technologies's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Agilent Technologies's last four quarterly filings that the numbers alone won't show?”